Takeda Receives Positive CHMP Opinion for Entyvio® (vedolizumab) in Europe for the Treatment of Ulcerative Colitis and Crohn's Disease


Osaka, Japan, March 24, 2014 – Takeda Pharmaceutical Company Limited (“Takeda”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive Opinion for Entyvio® (vedolizumab), a humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.1,2 UC and CD are the two most common types of inflammatory bowel disease (IBD),3 affecting more than four million people worldwide,4,5,6,7,8,9 including approximately 2.2 million Europeans.6

Read more


Top of page

Takeda Pharma